FLT3 Mutations in AML: Types, Prognosis, and Treatment

FLT3 mutations are among the most common genetic changes found in acute myeloid leukemia, turning up in roughly a quarter to a third of newly diagnosed adult cases and fundamentally altering both prognosis and treatment strategy. The FLT3 gene encodes a receptor on the surface of immature blood cells that normally helps regulate their growth and survival. When that gene mutates, the receptor gets stuck in an “always on” position, driving leukemia cells to multiply unchecked. Over the past decade, drugs designed specifically to block this runaway signal have reshaped how FLT3-mutated AML is treated, though the biology remains challenging enough that resistance and relapse are still central concerns.

What FLT3 Does in Healthy Blood Cells

FLT3 stands for FMS-like tyrosine kinase 3. In healthy bone marrow, FLT3 sits on the surface of early blood cell precursors, where it acts as a receiver for a signaling molecule called FLT3 ligand. When ligand binds the receptor, it triggers a cascade inside the cell that promotes growth, survival, and maturation into functioning white blood cells and other blood components.¹ The receptor is particularly important for the development of stem cells and the immune system, and its signaling activity is tightly regulated so that cells grow only when and where they should.²

Normally, FLT3 flips between an inactive (off) and active (on) state. A stretch of the protein called the juxtamembrane domain acts as a kind of wedge that holds the receptor in its inactive shape until the right signal arrives. This autoinhibition is what keeps FLT3 from firing when no ligand is present.³ When mutations disrupt that wedge, the receptor loses its off switch.

The Two Main Types of FLT3 Mutations

Two categories of FLT3 mutation dominate in AML. The more common and more clinically consequential is the internal tandem duplication, or ITD. An ITD is an extra stretch of duplicated DNA inserted into the juxtamembrane region of the gene. These insertions range from a handful of nucleotides to fairly large segments. The duplicated sequence physically disrupts the autoinhibitory wedge, making it impossible for FLT3 to hold itself in the off position. The result is a receptor that switches itself on without needing its normal ligand.⁴ Roughly one in four adult AML patients carry an FLT3-ITD mutation.⁵

The second type is a point mutation in the tyrosine kinase domain (TKD), most often at a position called D835. TKD mutations also lock FLT3 into an active state, but by a different structural mechanism: they destabilize the activation loop of the enzyme rather than disrupting the juxtamembrane wedge. TKD mutations appear in about 5% of AML patients.⁶ Their prognostic impact is generally considered milder than that of ITDs, and some studies have found that patients with TKD mutations alone fare similarly to those with unmutated FLT3.

When either mutation activates FLT3 constitutively, the receptor floods the cell with growth and survival signals through pathways that promote cell proliferation and block programmed cell death. ITD mutations are particularly problematic because the mutant receptor gets partially retained inside the cell rather than reaching the surface normally, and in that abnormal location it activates a signaling branch that wild-type FLT3 does not strongly engage.⁷ This aberrant signaling pattern is one reason ITDs carry a worse prognosis.

Why FLT3-ITD Worsens Prognosis

Before targeted drugs entered the picture, a diagnosis of FLT3-ITD AML was bad news. Patients with this mutation had higher relapse rates and shorter survival after standard chemotherapy compared with AML patients whose FLT3 was unmutated.⁸ Not all FLT3-ITDs are created equal, though. Two features of the mutation itself strongly influence how dangerous it is.

The first is the allelic ratio, which reflects how much of the FLT3 in a patient’s leukemia cells is mutated versus normal. A high allelic ratio (meaning the mutant version dominates) is associated with significantly worse overall and event-free survival.⁹ The second is the length of the duplicated segment. Longer ITDs also correlate with inferior outcomes. Patients who have either a high allelic burden or a long ITD represent a particularly poor prognostic subgroup.¹⁰

Co-occurring mutations further complicate the picture. For instance, patients who carry both an FLT3-ITD and a mutation in the NPM1 gene sometimes have outcomes closer to intermediate risk rather than poor risk, depending on the allelic ratio. Current risk-stratification systems from groups like the European LeukemiaNet factor in FLT3-ITD status alongside NPM1 and other mutations to guide treatment decisions, particularly around whether to pursue a stem cell transplant in first remission.

Frontline Treatment With FLT3 Inhibitors

The approval of midostaurin in 2017 marked a turning point. The landmark RATIFY trial showed that adding midostaurin to standard chemotherapy during induction and consolidation improved four-year overall survival from about 44% to roughly 51%, a statistically significant benefit. Complete remission rates also trended higher with midostaurin, reaching 68% compared with 61% in the control arm on an intent-to-treat basis. RATIFY was the first trial to prove that a targeted, biomarker-driven therapy could improve survival in AML, and it opened the door for further development of FLT3 inhibitors.¹¹

Midostaurin is a first-generation, multi-kinase inhibitor, meaning it blocks FLT3 but also hits several other kinases. Second-generation inhibitors are more selective. Quizartinib, approved more recently, specifically targets FLT3-ITD. The QuANTUM-First trial demonstrated that adding quizartinib to chemotherapy, followed by up to three years of quizartinib maintenance, improved overall survival in adults aged 18 to 75 with newly diagnosed FLT3-ITD-positive AML.¹² Quizartinib’s selectivity means fewer off-target effects, though it carries its own side-effect profile, including a risk of QT prolongation on heart monitoring that requires careful management.

The choice between midostaurin and quizartinib often depends on the specific mutation type. Midostaurin covers both ITD and TKD mutations, while quizartinib’s approval is limited to ITD-positive disease. For patients with TKD mutations, midostaurin remains the frontline option.

Treatment for Relapsed or Refractory Disease

When FLT3-mutated AML comes back after initial treatment or fails to respond, gilteritinib is the current standard targeted option. The ADMIRAL trial compared gilteritinib monotherapy to salvage chemotherapy in relapsed or refractory FLT3-mutated AML and found a median overall survival of 9.3 months with gilteritinib versus 5.6 months with chemotherapy. About a third of gilteritinib-treated patients achieved complete remission with full or partial blood count recovery, compared with about 15% on chemotherapy.¹³

Real-world data from multiple centers have confirmed gilteritinib’s activity outside of clinical trials, including in patients who were heavily pretreated or had already received prior FLT3 inhibitor therapy. In one multi-center analysis, about half of patients achieved a complete response, and those who did had substantially longer survival than non-responders.¹⁴ Overall, a systematic review and meta-analysis of randomized trials found that second-generation FLT3 inhibitors significantly improved overall survival in the relapsed or refractory setting compared with chemotherapy alone.¹⁵

Transplant and Post-Transplant Maintenance

Allogeneic stem cell transplant remains a key part of the treatment strategy for many FLT3-ITD patients, especially those at higher risk of relapse. Some institutions have adopted a policy of aggressively pursuing transplant in first complete remission for all FLT3-ITD patients, including from alternative donors when a matched sibling is unavailable. Data from single-institution cohorts suggest this approach can improve long-term outcomes for FLT3-ITD AML compared with chemotherapy alone.¹⁶

But transplant alone does not eliminate relapse risk, which is where post-transplant maintenance with a FLT3 inhibitor comes in. This is one of the more exciting developments in recent years. A large real-world analysis from the German stem cell transplant registry found that patients who received FLT3 inhibitor maintenance after transplant had a five-year relapse-free survival of 70% compared with 47% for those who did not, and five-year overall survival of 81% versus 57%.¹⁷ The benefit held regardless of measurable residual disease status, suggesting maintenance helps even when initial testing shows no detectable leukemia after transplant. Smaller studies have confirmed similar benefits when adjusting for conditioning regimen and donor type.¹⁸

What about patients who carry FLT3-ITD alongside other mutations like NPM1 or DNMT3A? A study focused on double and triple mutation combinations found that after transplant, the outcomes were comparable across these groups, suggesting that the transplant itself partly levels the prognostic playing field for these co-mutated patients.¹⁹

Triplet Regimens for Older or Less Fit Patients

Standard intensive chemotherapy is not an option for every AML patient. Older adults and those with significant medical problems often cannot tolerate the aggressive induction regimens used in younger patients. For this group, lower-intensity approaches built around a hypomethylating agent (like azacitidine) combined with venetoclax have become standard. Adding a FLT3 inhibitor to that doublet creates a “triplet” regimen, and early results have been striking.

In a study comparing triplet therapy to the standard doublet in older or unfit patients with FLT3-mutated AML, the triplet produced complete remission or complete remission with incomplete count recovery in 93% of patients versus 70% with the doublet. Just as important, the depth of response was meaningfully better: rates of undetectable residual disease by flow cytometry were more than double with the triplet approach. Median overall survival had not been reached in the triplet group at the time of analysis, compared with 9.5 months for the doublet.²⁰

Longer-term follow-up has confirmed that these high response rates hold up over time, with a composite complete remission rate of 93% in a retrospective analysis of 73 patients who received frontline triplet therapy.²¹ However, patterns of relapse are still being characterized, and it remains unclear how durable these responses will be over many years. The field is watching these data closely, especially since triplet therapy represents a potentially less toxic path to deep remission for patients who would otherwise have limited options.

Why FLT3 Inhibitors Stop Working

Resistance to FLT3 inhibitors is one of the most frustrating aspects of treating this disease. Even when patients respond well initially, the leukemia often finds a way around the drug. One well-characterized escape route involves secondary mutations in the FLT3 gene itself. The most notorious is the F691L “gatekeeper” mutation, which alters the drug-binding pocket of the FLT3 protein enough to prevent gilteritinib from latching on effectively. Computational studies have shown that this single amino acid change induces conformational shifts in the activation loop and other key structural elements of the protein, reducing the drug’s binding strength.²²

But on-target resistance (mutations in FLT3 itself) is only part of the story. Leukemia cells can also develop off-target resistance by activating alternative survival pathways that bypass FLT3 entirely. Mutations in genes like RAS, IDH1, or IDH2 can emerge during FLT3 inhibitor treatment, giving the leukemia a new growth signal that is independent of FLT3. This is one reason combination approaches, like the triplet regimens described above, are attractive: hitting the leukemia through multiple mechanisms simultaneously makes it harder for the cells to escape through any single back door.

How FLT3 Mutations Are Detected

Knowing a patient has a FLT3 mutation, and knowing its characteristics, is essential for treatment decisions. The traditional method for detecting FLT3-ITD is PCR-based fragment analysis. A fragment of the FLT3 gene is amplified and run on a gel or capillary electrophoresis system, where the duplicated segment shows up as a larger-than-normal band. This approach can also quantify the allelic ratio by comparing the size of the mutant and normal peaks.

Next-generation sequencing panels are now widely used in leukemia workups and can detect FLT3-ITD alongside dozens of other mutations in a single test. However, ITDs pose a technical challenge for standard sequencing pipelines because the duplicated segments can be large and repetitive, which some alignment algorithms handle poorly. Studies comparing NGS to fragment analysis have found good overall concordance, with about 94% of cases matching in allelic ratio classification using a cutoff of 0.5.²³ When discrepancies arise, NGS tends to underestimate the allelic ratio compared with fragment analysis, which matters because allelic ratio informs risk stratification.²⁴ For this reason, some institutions still run fragment analysis alongside NGS panels to ensure accurate ITD quantification.²⁵

Speed matters here. Because FLT3 status can determine whether a patient receives a targeted inhibitor during induction, testing needs to be completed fast, ideally within a few days of diagnosis. Delays in mutation results can delay treatment decisions, which is a real concern in a disease where early intervention affects outcomes.

FLT3 Mutations in Children

FLT3-ITD occurs less frequently in pediatric AML than in adults, appearing in about 12% of children with newly diagnosed disease. But when it does appear, the prognostic impact follows the same allelic-ratio pattern seen in adults: children with a high ITD allelic ratio (above 0.4) have markedly worse progression-free survival than those with lower ratios or no FLT3 mutation at all. In one large pediatric study, four-year progression-free survival for children with a high allelic ratio was just 16%, compared with 72% for those with low-ratio ITDs and 55% for those with unmutated FLT3.²⁶

Most of the FLT3 inhibitor clinical trial data comes from adult populations, and the use of these drugs in children has lagged somewhat behind. In the pre-FLT3-inhibitor era, pediatric outcomes for FLT3-ITD-mutated AML were driven largely by standard chemotherapy and transplant decisions. A review of 18 pediatric patients treated before FLT3 inhibitors were routinely available highlighted common features of this population: a median age at diagnosis around 13 years, frequent normal cytogenetics, and a predominance of certain leukemia subtypes.²⁷ Trials incorporating FLT3 inhibitors into pediatric regimens are ongoing and represent an important area of unmet need.

Antibody-Drug Conjugates Targeting FLT3

FLT3 inhibitors work by blocking the enzymatic activity of the mutated receptor from the inside. An entirely different approach is to target the FLT3 protein from the outside using antibody-drug conjugates, or ADCs. These are engineered molecules that combine an antibody, which recognizes FLT3 on the leukemia cell’s surface, with a potent toxin payload. When the ADC binds FLT3 and gets pulled inside the cell, the toxin is released, killing the cell from within.

The appeal of this strategy is that it does not depend on the receptor being mutated. ADCs target FLT3 as a surface marker, meaning they could potentially work against leukemia cells expressing normal FLT3, not just those with ITD or TKD mutations. Preclinical work on a novel FLT3-targeting ADC has shown promising activity, including when combined with kinase inhibitors.²⁸ This is still early-stage research, but it hints at a future where FLT3 is targeted simultaneously from the outside and the inside, potentially making resistance harder to develop. The broader question of whether the field can combine FLT3-directed kinase inhibitors, ADCs, and other immunotherapy platforms into effective and tolerable regimens will shape the next decade of treatment development.